Leustatin

Cladribine, the active ingredient in Leustatin, is a purine nucleoside analog presented as a sterile injectable solution for subcutaneous administration. It is a prescription‑only antineoplastic agent indicated for the treatment of hairy cell leukemia in adult patients, targeting malignant B‑lymphocytes to achieve disease control. The drug is supplied in single‑dose vials and requires careful handling by qualified healthcare professionals.

GNH USA supplies Leustatin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide, providing regulatory‑approved product and logistics support for global distribution.

Cladribine is a purine nucleoside analog used in the management of hematologic malignancies, specifically targeting B‑cell lymphoproliferative disorders.

Hairy cell leukemia: induces remission and reduces disease burden in adult patients.

Cladribine may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Fatigue: persistent tiredness reported by many patients. - Nausea: mild to moderate upset stomach. - Fever: transient elevations in body temperature. - Injection site reactions: redness, swelling, or pain at the subcutaneous site. - Lymphopenia: reduced lymphocyte counts. - Mild infections: increased susceptibility to common colds or respiratory infections.

Serious or Rare Side Effects: - Severe infections: opportunistic or life‑threatening bacterial, viral, or fungal infections. - Profound neutropenia: markedly low neutrophil counts increasing infection risk. - Autoimmune hemolysis: destruction of red blood cells. - Tumor lysis syndrome: rapid tumor cell breakdown causing metabolic disturbances. - Secondary malignancies: rare development of new cancers. - Severe allergic reactions: anaphylaxis or hypersensitivity.

Patients receiving Leustatin should be monitored closely for safety and efficacy considerations.

Pregnancy: unknown safety; avoid unless benefits outweigh risks. Renal impairment: monitor renal function and adjust care as needed. Hepatic impairment: assess liver enzymes before and during therapy. Immunosuppression: watch for signs of infection and consider prophylaxis. Concomitant myelosuppressive therapy: increased risk of severe cytopenias. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Cladribine may interact with other agents that affect immune function or blood cell production.

Major Interactions (Avoid): - Live vaccines: may cause severe infection. - Concurrent myelosuppressive chemotherapy: can exacerbate bone‑marrow suppression.

Moderate Interactions (Monitor Closely): - Non‑live vaccines: reduced efficacy, monitor immune response. - Antimicrobial prophylaxis agents: potential additive toxicity. - NSAIDs: may increase risk of renal impairment. - Anticonvulsants inducing hepatic enzymes: possible alteration of drug metabolism.